Oncology Xagena
A Phase III study has shown that Lapatinib ( Tykerb ) and Capecitabine ( Xeloda ) versus Capecitabine alone nearly doubled time to progression ( 36.9 weeks in the combination arm versus 19.7 weeks wit ...
A Phase III study has shown that Lapatinib ( Tykerb ) and Capecitabine ( Xeloda ) versus Capecitabine alone nearly doubled time to progression ( 36.9 weeks in the combination arm versus 19.7 weeks wit ...
One-third of women with HER2-positive metastatic breast cancer currently develop brain metastases. Once the disease advances to this stage, overall disease prognosis is poor with the average one-yea ...
Using laboratory and mouse models of human breast cancer, researchers have found that a small molecule capable of targeting specific proteins on the surface of breast cancer cells can inhibit the grow ...
Use of Lapatinib ( Tykerb ) to delay tumor growth and improve the survival of patients with inoperable hepatocellular carcinoma, or liver cancer, only benefited certain subgroups of patients. While ...
In the advanced breast cancer, one study has found that if Sorafenib ( Nexavar ) is combined with the chemotherapy drug, Capecitabine ( Xeloda ), it makes a significant difference to the time women li ...
The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Kadcyla, 100 mg and 160 mg, ...
Surgery for colorectal liver metastases results in an overall survival of about 40% at 5 years. Progression-free survival is increased with the addition of Oxaliplatin ( Eloxatin ) and Fluorouracil ch ...
Surgery for colorectal liver metastases results in an overall survival of about 40% at 5 years. Progression-free survival is increased with the addition of Oxaliplatin ( Eloxatin ) and Fluorouracil ( ...
Prolonging first-line chemotherapy results with maintenance treatment may influence overall survival. In HER2-negative patients with locally recurrent/metastatic breast cancer, combining Bevacizumab ( ...
Combining Bevacizumab ( Avastin ) with first- or second-line chemotherapy in randomised phase III trials showed significantly improved progression-free survival in HER2-negative locally recurrent / me ...
Cancer Drugs Fund ( CDF ) Panel has assessed the application for Eribulin ( Halaven ) to remain in the CDF list as 3rd line chemotherapy for patients with locally advanced or metastatic breast c ...
The Cancer Drugs Fund ( CDF ) Panel has assessed the application for Eribulin ( Halaven ) to enter the CDF as an option for patients with locally advanced or metastatic HER-2 negative breast can ...
